Skip to content

13F-HR filed by Remedium Capital Partners, LLC

Remedium Capital Partners, LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-13 18:30:46 UTC, with 6 holding rows worth $273,591,243.

Accession
0002104501-26-000021
Filed
2026-11-13
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 6 entries on the cover page, a total value of $273,591,243 stated on the cover page (in dollars after the unit check, H1), rows summing to $273,591,243 with VALUE read as dollars as filed, 13F file number 028-26277. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPYRE THERAPEUTICS INC00773J202COM NEW1,160,620$103,329,999dollars as filed
ORUKA THERAPEUTICS INC COM687604108Stock954,150$79,471,154dollars as filed
DAMORA THERAPEUTICS INCG2646Y104COMM STK2,045,473$43,527,665dollars as filed
JADE BIOSCIENCES INC008064206COM NEW1,807,814$25,399,787dollars as filed
KORSANA BIOSCIENCES INC23255M303COMMON STOCK518,500$16,592,000dollars as filed
CRESCENT BIOPHARMA INCG2545C104COMMON STOCK361,250$5,270,638dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0002104501-26-000021this filing2026-11-13